Cabozanitinib in combination with atezolizumab for advanced kidney cancer

This phase Ib study reports the results of a combination of cabozantinib plus atezolizumab in people with advanced clear cell and non–clear cell renal cell carcinoma (RCC). The number and nature of side effects to the 40 mg and 60 mg dose of cabozantinib were similar. Around two thirds of patients reported side effects to […]

read more

Lenvatinib plus pembrolizumab in for untreated and previously treated metastatic kidney cancer

Results from a phase Ib/II study looking at lenvatinib plus pembrolizumab for the treatment of metastatic renal cell carcinoma (RCC) showed that there was a response to treatment and the cancer reduced in size (objective response) in 73% of patients who had not received previous medication for their cancer. There were 143 patients in the […]

read more

ASCO GU 2021: Combination of HIF-2α inhibitor and cabozantinib is active in previously treated advanced kidney cancer

In a small phase 2 study presented at the virtual American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU), the novel hypoxia-inducible factor 2α (HIF-2α) inhibitor, belzutifan (MK-6482), showed promising anti-cancer activity in combination with cabozantinib in patients with metastatic clear cell renal cell carcinoma (RCC) that had been previously treated. Kidney cancers develop […]

read more

Checkpoint inhibitor re-challenge after immune-related adverse events

Immunotherapy has revolutionised treatment in many cancers, including renal cell carcinoma (RCC). This study looked at giving patients immunotherapy after they had experienced an immune-related adverse event. With nivolumab in RCC, the probability of having a severe or life-threatening adverse event is very low. Nivolumab alone is very well tolerated. However, with the ipilimumab plus […]

read more

Safety and efficacy of tivozanib–nivolumab combination in patients with metastatic kidney cancer

In this phase 1b/2 study the researchers looked at a combination of tivozanib and nivolumab in 25 patients with metastatic renal cell carcinoma (RCC). Tivozanib is a targeted therapy called a vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI) that blocks the growth of blood vessels to the tumour, while nivolumab is an immune […]

read more

Immune-related adverse events from cabozantinib plus atezolizumab as first-line treatment for advanced kidney cancer

The COSMIC-021 clinical trial investigated a combination of cabozantinib and atezolizumab in untreated clear-cell renal cell carcinoma (RCC). In this video interview, Dr Monty Pal from the City of Hope Hospital in California discusses the side effects from this combination of drugs. There were two groups of patients; one on 60 mg of cabozantinib plus […]

read more

ESMO Virtual 2020: Impact of immunotherapy on quality of life

In this video interview, Dr Jeffrey Kirshner from the Haematology-Oncology Associates of Central New York Community Clinical Oncology Programme talks about a global review of data on quality of life in patients on immunotherapy that was presented at this year’s ESMO.  During the interview, Dr Kirshner mentions that quality of life is better with immunotherapy than […]

read more

Sapanisertib is tolerable and shows activity in advanced kidney cancer

In a phase I study to look at the safety and tolerability of a new drug called sapanisertib, sapanisertib was well-tolerated and showed some anti-tumour activity in patients with renal cell carcinoma (RCC) and endometrial cancer. Sapanisertib is an oral, highly selective inhibitor of the mTORC1/mTORC2 receptors in advanced solid tumours. In the study, 82 […]

read more

Patients ‘left in the dark’ by the NHS over cancer treatments

Macmillan Cancer Support has recently published the results from their annual Cancer Patient Experience Survey, which reveals that around 120,000 cancer patients a year feel that topics, such as treatments and side effects, were not fully explained to them by NHS staff. This made them feel “left in the dark” by the NHS. Thirty-nine percent […]

read more

Selecting therapy for poor-risk advanced kidney cancer

In this video interview, Dr Earle Burgess from the Levine Cancer Centre in the USA talks about the factors that are considered when selecting therapy for patients with poor-risk advanced renal cell carcinoma (RCC). Such factors include the risk status of the patient, burden or sites of disease, co-morbidities such as hypertension and cardiac disease, […]

read more
Showing 1 to 10 of 26 results
  TOP